Cargando…

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

BACKGROUND: Over a dozen disease-modifying therapies (DMTs) have been approved for treatment of multiple sclerosis (MS). Treatment guidelines focus on when to initiate, change, and discontinue treatment but provide little guidance on how to select or sequence DMTs. This study assessed sequencing pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Robert J., Mehta, Rina, Pham, Timothy, Park, Julie, Wilson, Kathleen, Bonafede, Machaon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172015/ https://www.ncbi.nlm.nih.gov/pubmed/35672686 http://dx.doi.org/10.1186/s12883-022-02738-7

Ejemplares similares

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
por: Bonafede, Machaon, et al.
Publicado: (2020)

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Bowen, James, et al.
Publicado: (2020)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
por: Johnson, Barbara H., et al.
Publicado: (2015)

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls
por: Bedenbaugh, Angela V, et al.
Publicado: (2021)

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Freeman, Leorah, et al.
Publicado: (2021)

Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data
por: Beyrer, Julie, et al.
Publicado: (2021)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
por: Bonafede, Machaon, et al.
Publicado: (2018)

Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept
por: Bonafede, Machaon, et al.
Publicado: (2020)

A Linked Electronic Medical Record-Claims Analysis of the Clinical and Economic Outcomes of Patients Coded for Erosive Esophagitis in the United States
por: Yadlapati, Rena, et al.
Publicado: (2023)

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
por: McArthur, C., et al.
Publicado: (2023)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
por: Kim, Su-Hyun, et al.
Publicado: (2019)

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
por: Graf, Jonas, et al.
Publicado: (2023)

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2021)

Correction to: Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2022)

Identification of Acute Giant Cell Arteritis in Real‐World Data Using Administrative Claims‐Based Algorithms
por: Lee, Hemin, et al.
Publicado: (2021)

Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis
por: Song, Xue, et al.
Publicado: (2019)

Body Mass Index Variable Interpolation to Expand the Utility of Real-world Administrative Healthcare Claims Database Analyses
por: Wu, Bingcao, et al.
Publicado: (2021)

CO56 Real-World Effectiveness of Early Treatments for COVID-19: Evidence from Administrative Claims Data
por: Bell, C., et al.
Publicado: (2023)

Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data
por: Ohlmeier, Christoph, et al.
Publicado: (2020)

A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping
por: Singer, Barry A, et al.
Publicado: (2021)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan
por: Kagawa, Y., et al.
Publicado: (2023)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression
por: Truong, Chi T. L., et al.
Publicado: (2021)

Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
por: Burt, Richard K., et al.
Publicado: (2021)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Descriptive Analysis of the Direct Medical Costs of Multiple Sclerosis in 2004 Using Administrative Claims in a Large Nationwide Database
por: Prescott, Jeff D., et al.
Publicado: (2007)

Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data
por: Princic, Nicole, et al.
Publicado: (2016)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r824ibd7ubtet8vr50aiqrkipu